PharmaCyte Biotech Inc (PMCB)

[$Pistol Pete$]

Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc.

Oct 22, 2014 07:30:00 (ET)

NEW YORK, Oct. 22, 2014 /PRNewswire/ -- Nuvilex, Inc. (OTCQB: NVLX) -- According to the International Diabetes Federation, approximately 400 million people worldwide are living with diabetes, with that number expected to grow to 552 million people by 2030. The global market for diabetes treatments is approximately $500 billion.

In 2012 approximately 330,000 people worldwide died from pancreatic cancer. Pancreatic cancer is the fourth most common cause of death due to cancer in the United States, and according to a report in the May 19, 2014 edition of Cancer Research, it is forecast to become the second deadliest cancer in the United States by 2030. The worldwide market for treatments that battle this disease exceeds $9 billion annually.

Nuvilex is a clinical stage a biotechnology company, developing and preparing to commercialize treatments for pancreatic cancer, breast cancer, brain cancer, and diabetes through a cellulose-based live cell encapsulation technology known as "Cell-in-a-Box(R)". The company primarily focuses on the advancement of its treatment for advanced, inoperable pancreatic cancer by combining Cell-in-a-Box(R) technology with the anti-cancer drug ifosfamide. The company, through its subsidiary, Medical Marijuana Sciences, Inc., is developing ways to exploit the use of live cell encapsulation technology in optimizing cancer effectiveness with cannabinoids against cancers, while minimizing or eliminating the debilitating side effects usually associated with cancer treatments. The company is developing these "green" approaches to fighting deadly cancers affecting hundreds of thousands of individuals worldwide every year.

A brief analyst report on NVLX that includes recent events, stock's technical outlook and analyst comments can be viewed by using the following link at no cost:

http://bit.ly/-NVLX--AnalystReport

Copy and paste to browser may be required.

Forward-Looking Disclaimer

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

Not Financial Advice

BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Compliance Procedure

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nuvilex-brief-analyst-report-thinking-outside-the-box-by-brokerbank-securities-inc-369528303.html

SOURCE BrokerBank Securities, Inc.